JPWO2021076514A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021076514A5 JPWO2021076514A5 JP2022521584A JP2022521584A JPWO2021076514A5 JP WO2021076514 A5 JPWO2021076514 A5 JP WO2021076514A5 JP 2022521584 A JP2022521584 A JP 2022521584A JP 2022521584 A JP2022521584 A JP 2022521584A JP WO2021076514 A5 JPWO2021076514 A5 JP WO2021076514A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- use according
- treatment period
- platelet count
- itp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962914688P | 2019-10-14 | 2019-10-14 | |
| US62/914,688 | 2019-10-14 | ||
| US201962951302P | 2019-12-20 | 2019-12-20 | |
| US62/951,302 | 2019-12-20 | ||
| PCT/US2020/055410 WO2021076514A1 (fr) | 2019-10-14 | 2020-10-13 | Procédé de traitement de la thrombocytopénie immunitaire par l'administration de (r)-2-[3-[4-amino-3-(2-fluoro-4-phénoxy-phényl)pyrazolo[3,4-d]pyrimidine-1-yl]pipéridine-1-carbonyle]-4-méthyl-4-[4-(oxétane-3-yl)pipérazine-1-yl]pent-2-ènenitrile |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022550919A JP2022550919A (ja) | 2022-12-05 |
| JPWO2021076514A5 true JPWO2021076514A5 (fr) | 2023-10-20 |
Family
ID=73040359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022521584A Pending JP2022550919A (ja) | 2019-10-14 | 2020-10-13 | （ｒ）－２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペンタ－２－エンニトリルを投与することにより免疫性血小板減少症を治療する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20210106584A1 (fr) |
| EP (1) | EP4045051A1 (fr) |
| JP (1) | JP2022550919A (fr) |
| KR (1) | KR20220080179A (fr) |
| CN (1) | CN115209899A (fr) |
| AU (1) | AU2020365951A1 (fr) |
| CA (1) | CA3154257A1 (fr) |
| CO (1) | CO2022006087A2 (fr) |
| IL (1) | IL291994A (fr) |
| MX (1) | MX2022004427A (fr) |
| TW (1) | TW202128175A (fr) |
| WO (1) | WO2021076514A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202308638A (zh) * | 2021-04-16 | 2023-03-01 | 美商普林斯匹亞生物製藥公司 | 藉由投予特定化合物治療藥物及疫苗誘發的免疫性血小板減少症之方法 |
| WO2024097667A1 (fr) * | 2022-10-31 | 2024-05-10 | Principia Biopharma Inc. | Méthodes de traitement de thrombocytopénie immunitaire par administration de (r)-2-[3- [4-amino-3-(2-fluoro-4-phénoxy-phényl)pyrazolo[3,4-d]pyrimidin-l-yl]pipéridine-l-carbonyl]-4-méthyl-4-[4-(oxétan-3-yl)pipérazin-l-yl]pent-2-ènenitrile |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2731833T3 (es) | 2012-09-10 | 2019-11-19 | Principia Biopharma Inc | Compuestos pirazolopirimidínicos comos inhibidores de cinasas |
| US10092569B2 (en) | 2014-02-21 | 2018-10-09 | Principia Biopharma Inc. | Salts and solid form of a BTK inhibitor |
| MX2017007973A (es) | 2014-12-18 | 2018-02-09 | Principia Biopharma Inc | Tratamiento de penfigo. |
| CN107427468B (zh) | 2014-12-24 | 2022-02-25 | 普林斯匹亚生物制药公司 | Btk抑制剂的部位特异性给药 |
| AU2017290354C1 (en) | 2016-06-29 | 2023-07-06 | Principia Biopharma Inc. | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
-
2020
- 2020-10-13 US US17/069,218 patent/US20210106584A1/en not_active Abandoned
- 2020-10-13 AU AU2020365951A patent/AU2020365951A1/en active Pending
- 2020-10-13 EP EP20800510.8A patent/EP4045051A1/fr active Pending
- 2020-10-13 MX MX2022004427A patent/MX2022004427A/es unknown
- 2020-10-13 IL IL291994A patent/IL291994A/en unknown
- 2020-10-13 CN CN202080085817.7A patent/CN115209899A/zh active Pending
- 2020-10-13 CA CA3154257A patent/CA3154257A1/fr active Pending
- 2020-10-13 KR KR1020227015963A patent/KR20220080179A/ko unknown
- 2020-10-13 JP JP2022521584A patent/JP2022550919A/ja active Pending
- 2020-10-13 TW TW109135399A patent/TW202128175A/zh unknown
- 2020-10-13 WO PCT/US2020/055410 patent/WO2021076514A1/fr active Application Filing
-
2022
- 2022-05-11 CO CONC2022/0006087A patent/CO2022006087A2/es unknown
- 2022-09-16 US US17/946,585 patent/US20230124267A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6576469B2 (ja) | 心不全の治療のためのサクビトリル−バルサルタンの用量計画 | |
| WO2007050379A2 (fr) | Prevention de l'infectiosite bacterienne ou virale et composition contenant un additif de prevention d'infection | |
| JP2023065398A (ja) | リルゾールの舌下製剤 | |
| JP2005508346A (ja) | 免疫炎症疾患の治療のための組合せ | |
| JP2022116304A (ja) | 血液がんの治療のためのＰＰＡＲγアゴニスト | |
| JP2022536623A (ja) | 肺動脈性肺高血圧症の治療方法 | |
| US20220211674A1 (en) | Thromboxane Receptor Antagonists in AERD/Asthma | |
| JP2005508983A (ja) | Ｐｄｅ４又はｐｄｅ３／４阻害剤及び抗リウマチ薬の複合薬 | |
| JP4007615B2 (ja) | 自己免疫性疾患の処置用薬剤組成物 | |
| JP2000513331A (ja) | 鬱病の治療におけるパロキセチン | |
| JPWO2021076514A5 (fr) | ||
| AU2020235442A1 (en) | Capsid assembly modulator solid formulation | |
| WO2017148129A1 (fr) | Composition pharmaceutique destinée au traitement de la cachexie et son utilisation | |
| JP2023536944A (ja) | 疾患の治療におけるｂｔｋ阻害剤の使用 | |
| JP6420923B1 (ja) | 医薬 | |
| WO2021145356A1 (fr) | Composition pharmaceutique destinée au traitement, à la prévention et/ou à l'inhibition de la progression de la myopie | |
| JPH05310573A (ja) | リウマチ治療薬 | |
| US11648252B2 (en) | Methotrexate for use as a medicament | |
| AU2002362753B2 (en) | Compositions for and methods of treating and preventing sirs/sepsis | |
| EP4161499A1 (fr) | Utilisation d'une combinaison de colchicine et d'un inhibiteur cxcr-2 pour le traitement ou la prévention de la fièvre méditerranéenne familiale (fmf) et ses poussées | |
| JP2863534B2 (ja) | 医薬組成物 | |
| Jackson et al. | Pharmacokinetics and Effect on Type 2 Biomarker Levels of Dupilumab Weight Tiered-Based Dose Regimens in Patients Aged 6 to 11 Years with Uncontrolled, Moderate-to-Severe Asthma | |
| WO2022206752A1 (fr) | Combinaison médicamenteuse d'un agoniste du récepteur 7 de type toll et d'un anticorps anti-pd-l1 | |
| WO2023083281A1 (fr) | Utilisation d'un dérivé quinolinone dans le traitement de la thrombocytopénie immunitaire | |
| JPWO2021067506A5 (fr) |